NEW YORK, Oct. 9, 2018 /PRNewswire/ -- TAVI in Europe is approved for the treatment of severeaortic stenosis for symptomatic patients at intermediate, high or extreme risk for open heart surgery. Low-risk patients represent the next frontier in the TAVI market. Expansion into the low-risk population may prove to be more challenging than the
View original content:http://www.prnewswire.com/news-releases/transcatheter-aortic-valve-implantation-market-europe-units-sold-average-selling-prices-forecasts-2018-2024-medcore-300727908.html
Subscribe to our Free Newsletters!
Graviola''s health benefits range from curing headaches to fighting cancer. Read on to know more ...
Gene therapy is a specialized procedure where genetic material is introduced into the cells of a ...
The orange-like citrus fruit, Kumquat, is a complete health booster if included regularly in your ...View All